Table 2

Immunohistochemical (IHC) results in a validation set of 84 FLs, including 42 t(14;18)-positive and 42 t(14;18)-negative FL

Antibodies (IHC)t(14;18)+t(14;18)P
CD10   < .01 
    Negative 0/42 (0) 12/38 (31.6)  
    Positive 42/42 (100) 26/38 (68.4)  
BCL6   — 
    Positive 40/40 (100) 38/38 (100)  
IRF4/MUM1   .039 
    No greater than 10% 42/42 (100) 31/35 (88.6)  
    Greater than 10% 0/0 (0) 4/35 (11.4)  
IRF8   NS 
    Negative 3/39 (7.7) 1/38 (2.6)  
    Positive 36/39 (92.3) 37/38 (97.4)  
Ki67   < .01 
    No greater than 25% 17/41 (41.5) 3/33 (9.1)  
    Greater than 25% 24/41 (58.5) 30/33 (90.9)  
GRZMB   < .01 
    No greater than 3% 29/36 (80.6) 16/35 (45.7)  
    Greater than 3% 7/36 (19.4) 19/35 (54.3)  
FOXP3   NS 
    No greater than 5% 19/40 (47.5) 11/36 (30.55)  
    Greater than 5% 21/40 (52.5) 25/36 (69.4)  
CD57   NS 
    No greater than 15% 33/40 (82.5) 35/37 (94.6)  
    Greater than 15% 7/40 (17.5) 2/37 (5.4)  
Antibodies (IHC)t(14;18)+t(14;18)P
CD10   < .01 
    Negative 0/42 (0) 12/38 (31.6)  
    Positive 42/42 (100) 26/38 (68.4)  
BCL6   — 
    Positive 40/40 (100) 38/38 (100)  
IRF4/MUM1   .039 
    No greater than 10% 42/42 (100) 31/35 (88.6)  
    Greater than 10% 0/0 (0) 4/35 (11.4)  
IRF8   NS 
    Negative 3/39 (7.7) 1/38 (2.6)  
    Positive 36/39 (92.3) 37/38 (97.4)  
Ki67   < .01 
    No greater than 25% 17/41 (41.5) 3/33 (9.1)  
    Greater than 25% 24/41 (58.5) 30/33 (90.9)  
GRZMB   < .01 
    No greater than 3% 29/36 (80.6) 16/35 (45.7)  
    Greater than 3% 7/36 (19.4) 19/35 (54.3)  
FOXP3   NS 
    No greater than 5% 19/40 (47.5) 11/36 (30.55)  
    Greater than 5% 21/40 (52.5) 25/36 (69.4)  
CD57   NS 
    No greater than 15% 33/40 (82.5) 35/37 (94.6)  
    Greater than 15% 7/40 (17.5) 2/37 (5.4)  

Values are n (%).

NS indicates not significant.

or Create an Account

Close Modal
Close Modal